LEBRIKIZUMAB IMPROVES CLINICAL MANIFESTATIONS AND PATIENT-REPORTED OUTCOMES IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: PHASE 2B STUDY RESULTS

被引：0

作者：

Ali, Z. ^{[1
]}

Guttman-Yassky, E. ^{[2
]}

Blauvelt, A. ^{[3
]}

Eichenfield, L. ^{[4
]}

Paller, A. ^{[5
,6
]}

Armstrong, A. ^{[7
]}

Drew, J. ^{[8
]}

Gopalan, R. ^{[8
]}

Simpson, E. ^{[9
]}

机构：

[1] Copenhagen Univ Hosp Bispebjerg, Dept Dermatol, Copenhagen, Denmark

[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[3] Oregon Med Res Ctr, Portland, OR USA

[4] Univ Calif San Diego, Rady Childrens Hosp, Dept Dermatol, San Diego, CA 92103 USA

[5] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA

[6] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA

[7] Univ Southern Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA 90007 USA

[8] Dermira Inc, Menlo Pk, CA USA

[9] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P22

引用

页码：32 / 32

页数：1